BI Asset Management Fondsmaeglerselskab A S Purchases 2,731 Shares of Revvity Inc. $RVTY

Key Points

• BI Asset Management Fondsmaeglerselskab A S increased its holdings in Revvity Inc. by 68.0%, owning 6,747 shares valued at $714,000 at the end of the first quarter.
• Revvity reported $1.18 EPS for the last quarter, exceeding analysts' expectations, with a revenue of $720.28 million.
• The company announced a quarterly dividend of $0.07 per share, to be paid on November 7th, with a yield of 0.3%.

BI Asset Management Fondsmaeglerselskab A S boosted its position in Revvity Inc. (NYSE:RVTY - Free Report) by 68.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 6,747 shares of the company's stock after acquiring an additional 2,731 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Revvity were worth $714,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Nomura Holdings Inc. purchased a new stake in Revvity during the 4th quarter worth $447,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of Revvity by 3.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,139 shares of the company's stock valued at $544,000 after purchasing an additional 187 shares during the period. Ritholtz Wealth Management bought a new position in shares of Revvity in the first quarter valued at approximately $210,000. Amalgamated Bank boosted its holdings in shares of Revvity by 1.0% in the first quarter. Amalgamated Bank now owns 23,777 shares of the company's stock valued at $2,516,000 after acquiring an additional 227 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Revvity by 11.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,415 shares of the company's stock worth $1,417,000 after buying an additional 1,343 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Price Performance

Shares of RVTY stock traded down $2.53 during trading hours on Wednesday, hitting $88.70. The company had a trading volume of 940,156 shares, compared to its average volume of 1,179,040. Revvity Inc. has a 12 month low of $85.12 and a 12 month high of $129.50. The firm's fifty day moving average is $94.43 and its 200 day moving average is $98.51. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33. The firm has a market capitalization of $10.30 billion, a price-to-earnings ratio of 37.58, a PEG ratio of 2.47 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The company had revenue of $720.28 million during the quarter, compared to analysts' expectations of $711.26 million. During the same quarter in the previous year, the company posted $1.22 earnings per share. Revvity's quarterly revenue was up 4.1% compared to the same quarter last year. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, sell-side analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity's dividend payout ratio is presently 11.86%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RVTY shares. Raymond James Financial reaffirmed an "outperform" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Stifel Nicolaus cut their price target on shares of Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a report on Tuesday, July 29th. The Goldman Sachs Group cut their price target on shares of Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Finally, Bank of America decreased their price target on shares of Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Ten research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $120.07.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.